Merck Reports the Health Canada’s Approval of Keytruda to Treat MSI-H or dMMR Solid Tumors
Shots:
- Health Canada has approved Keytruda monotx. for treating adult and pediatric patients with unresectable or metastatic MSI-H or dMMR solid tumors, supported by KEYNOTE-158, KEYNOTE-164 & KEYNOTE-051 trials in >30 types of cancers
- The trial investigated 504 patients with MSI-H or dMMR cancer across 3 studies, KEYNOTE-164 (124 advanced MSI-H/dMMR colorectal cancer patients), KEYNOTE-158 (373 advanced non-colorectal cancer patients) & KEYNOTE-051 (7 pediatric patients with MSI-H/dMMR cancers)
- The combined analysis of adult patients showed a 34% ORR (11% CR & 23% PR). Median follow-up was 20.5mos. for adults & 5.2mos. for pediatric patients. Among 497 adults, 75% had responses lasting ≥36mos., with mDoR of 63.2mos.
Ref: Merck | Image: Merck
Related News:- GI Innovation Join Forces with Merck to Evaluate GI-102 Plus Keytruda for Treating Various Cancers
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
